Couple of nerds from Johns Hopkin have launched a platform to imitate genomes and prevent disease.
|1. Fundraising Target?||$1070000|
|2. Fundraised So Far?||$435794|
|3. Pre-Money Valuation?||$5500000|
|4. Previous Year's Annual Revenue||$0|
|5. Previous Year's Annual Net Income (+ Profitable, - Burning Cash)||~$39775|
The 6 Calacanis Characteristics ("Sow Passion, Not easy mediocrity", or S2 P6 N18)
|1. A startup that is based in SV?||True: Mountain View, CA|
|2. Has at least 2 founders?||True: Two|
|3. Has product in the market?||False: No Revenue|
|4. 6 months of continuous user growth or 6 months of revenue?||False: No product|
|5. Notable investors?||False: No one I recognize|
|6. Post-funding, will have 18 months of runway?||True: Low burn|
|1. Engineering?||1||No product in the marketplace|
|2. Timing?||1||Not sure why this timing is right for genome sequencing for preventive diseases|
|3. Monopoly?||1||No market share|
|4. People?||2||Cofounders are nerds from Johns Hopkins with no formal business executive experience|
|5. Distribution?||1||Bad distribution|
|6. Durability?||3||If they can build it, definitely durable|
|7. Secret?||1||Now is the perfect time to launch a genome sequencing preventive data platform for disease|
What has to go right for the startup to return money on investment:
1. Launch a product; 2. Make it generate revenue; 3. Predict disease accurately
What the Risks Are
1. Launching a product; 2. B2B vs. B2C; 3. Cofounders don't have business experience
Bonus Muhan's Notes
This is where I’ll post updates about the company. This way all my notes from offering to post-offering updates will be on one page.
Review these deal memos every time the startup raises a new round
Test if original thesis still applies
Notice trends in how you think
So, did I invest?Click here to find out.
Other thoughts, questions, comments, or concerns? Write me at email@example.com and let me know.